Katie Stockton breaks down the charts in Bristol-Myers, J&J and Pfizer.
Eli Lilly and Co. has gained roughly 63% this year, outperforming the S & P 500 Pharmaceuticals index by over 40%. The strong outperformance from LLY has been associated with strong underperformance by other high-profile stocks within the industry group. They may be ready to catch up, according to the charts. Bristol-Myers Squibb Co . , Johnson & Johnson , and Pfizer Inc . are three examples of pharmaceutical stocks that have been out of favor. All three have cyclical downtrends in place.
All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY .
Click here for the full disclaimer.
Johnson & Johnson Bristol-Myers Squibb Co Eli Lilly And Co Markets Breaking News: Markets Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
1 Stock to Buy, 1 Stock to Sell This Week: Eli Lilly, Walt DisneyStocks Analysis by Investing.com (Jesse Cohen) covering: Nasdaq 100, S&P 500, Dow Jones Industrial Average, Caterpillar Inc. Read Investing.com (Jesse Cohen)'s latest article on Investing.com
Read more »
Eli Lilly stock pops on annual guidance hike, strong Q2 top and bottom lineEli Lilly stock pops on annual guidance hike, strong Q2 top and bottom line
Read more »
Eli Lilly's blowout quarter should quiet investor concerns about the stockShares of the drugmaker jumped about 8% in Thursday trading after easily beating earnings expectations.
Read more »
Deutsche Bank says Eli Lilly stock is a buy — in line with our rating on sharesThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
10 things to watch in the stock market Friday including more bullishness on Eli LillyWall Street is lower Friday morning after a strong session Thursday extended the market comeback.
Read more »
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatmentsQuestions about whether Eli Lilly and Novo Nordisk can maintain their duopoly in weight loss drugs are fair game, but come 'too soon,' one analyst said.
Read more »